[1] FELDMAN D N, KIM L, RENE A G, et a1. Prognostic value of cardiac troponin-I or Troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis[J]. Catheter Cardiovasc Interv, 2011, 77(7): 1020-1030.
[2] ANG L, THANI K B, ILAPAKURTI M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention[J]. J Am Coll Cardiol, 2013, 61(1): 23-34.
[3] Fibrinogen Study Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis[J]. JAMA, 2005, 294(14): 1799-1809.
[4] THYGESEN K, ALPERT J S, JAFFE A S, et al. Third universal definition of myocardial infarction[J]. Eur Heart J, 2012, 33(20): 2551-2567.
[5] TRICOCI P, LEONARDI S, WHITE J, et al. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends [J]. J Am Coll Cardiol, 2013, 62(3): 242-251.
[6] DAVALOS D, AKASSOGLOU K. Fibrinogen as a key regulator of inflammation in disease[J]. Semin Immunopathol, 2012, 34(1): 43-62.
[7] TSIKARIS V. The anti-platelet approach targeting the fibrinogen ligand of the GPⅡB/Ⅲa receptor[J]. J Pept Sci, 2004, 10(10): 589-602.
[8] MAHMUD E, CAVENDISH J J, TSIMIKAS S, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention[J]. J Am Coll Cardiol, 2007, 49(22): 2163-2171.
[9] 鲁静朝, 崔炜, 都军, 等. 术前血浆 D-二聚体含量对择期经皮冠状动脉介入治疗术后心肌损伤的预测价值[J]. 中国循环杂志, 2004, 19(3): 180-182.
|